

## II. Claim Amendments

Claim 1 is amended in accordance with the Office Action's suggestion found on page 3 of the Office Action. Accordingly, claim 1 is amended to recite an administered amount of botulinum toxin effective to reduce a wrinkle, as well as reciting what subject has the wrinkle, here, a human subject.

Claims 36, 45 and 46 are amended to correct syntax of the claims and correlate the outcome of the method with the treatment method.

New claim 48 is added to claim a particular aspect of the invention and does not add new matter or raise additional issues, thus is also allowable.

III. Rejection of Claims 1-4, 10 and 12 under 35 U.S.C. 112, second paragraph

The Office Action rejects claims 1-4, 10 and 12 under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the applicant regards as the invention.

In accordance with the Office Action's suggestion, claim 1 has been amended to include the omitted step and what subject has the wrinkle, as discussed in section II of this submission, and is now in condition for allowance. Accordingly, dependent claims 2-4, 10 and 12 also include the added recitation found in amended claim 1 and are also in condition for allowance.

Thus, this rejection should be withdrawn.

VI. Conclusion

All issues raised in the Office Action have been addressed. Claims 36-39 and 43-47 are allowed. Examination and allowance of claims 1-4, 10, 12, and new claim 48 is respectfully requested.

Respectfully submitted,

/Claude L. Nassif/

Date: January 12, 2007

---

Claude L. Nassif, Ph.D.  
Registration Number 52,061

Address all inquires and correspondence to:

Claude L. Nassif, Ph.D.  
Allergan, Inc., Legal Department  
2525 Dupont Drive, T2-7H  
Irvine, CA 92612  
Telephone: 714 246 6458  
Fax: 714 246 4249